1. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis. (2nd January 2022) Authors: Rivera Duarte, Alfonso; Reece, Donna; Li, Xuan; Xu, Wei; Paul, Harminder; Masih-Khan, Esther; Winter, Andrew; Tiedemann, Rodger; Prica, Anca; Chen, Christine; Trudel, Suzanne; Kukreti, Vishal Journal: Amyloid Issue: Volume 29:Number 1(2022) Page Start: 23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains. (19th November 2021) Authors: Lebel, Eyal; Li, Xuan; Paul, Harminder; Masih‐Khan, Esther; Bhella, Sita; Chen, Christine; Prica, Anca; Reece, Donna; Tiedemann, Rodger; Trudel, Suzanne; Kukreti, Vishal Journal: European journal of haematology Issue: Volume 108:Number 3(2022) Page Start: 204 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*. Issue 1 (2nd January 2019) Authors: Chen, Christine I.; Paul, Harminder; Le, Lisa W.; Wei, Ellen N.; Snitzler, Susi; Wang, Trina; Levina, Olga; Kakar, Sumeet; Lau, Anthea; Queau, Michelle; Johnston, James B.; Smith, Deborah A.; Trudel, Suzanne Journal: Leukemia & lymphoma Issue: Volume 60:Issue 1(2019) Page Start: 92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Issue 7 (7th June 2021) Authors: Khan, Sahar; LeBlanc, Richard; Gyger, Martin; White, Darrell; Kaufman, Johnathan; Jazubowiak, Andrzej; Gul, Engin; Paul, Harminder; Le, Lisa W.; Lau, Anthea; Li, Zhihua; Trudel, Suzanne Journal: Leukemia & lymphoma Issue: Volume 62:Issue 7(2021) Page Start: 1721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL). Issue 4 (21st March 2019) Authors: Chen, Christine I.; Paul, Harminder; Snitzler, Susi; Kakar, Sumeet; Le, Lisa W.; Wei, Ellen N.; Lau, Anthea; Johnston, James B.; Gibson, Spencer B.; Queau, Michelle; Spaner, David; Croucher, Danielle; Sherry, Barbara; Trudel, Suzanne Journal: Leukemia & lymphoma Issue: Volume 60:Issue 4(2019) Page Start: 980 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment – validation of official dosing guidelines. Issue 8 (2nd July 2020) Authors: Chen, Christine I.; Cao, Yanshuo; Trudel, Suzanne; Reece, Donna E.; Kukreti, Vishal; Tiedemann, Rodger; Prica, Anca; Paul, Harminder; Le, Lisa W.; Levina, Olga; Kakar, Sumeet; Lau, Anthea; Chen, Hongzhuan; Chen, Eric Journal: Leukemia & lymphoma Issue: Volume 61:Issue 8(2020) Page Start: 1860 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long‐term follow‐up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia. (24th February 2014) Authors: Chen, Christine I.; Paul, Harminder; Wang, Trina; Le, Lisa W.; Dave, Nimisha; Kukreti, Vishal; Nong Wei, Ellen; Lau, Anthea; Bergsagel, Peter Leif; Trudel, Suzanne Journal: British journal of haematology Issue: Volume 165:Number 5(2014:Jun.) Page Start: 731 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗